TP53 Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about TP53 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

ALPINE: Maintenance Letrozole/Abemaciclib

Endometrial CancerTP53Recurrent Endometrial Cancer
Dana-Farber Cancer Institute32 enrolled6 locationsNCT06366347
Recruiting
Phase 2

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

TP53Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University24 enrolled1 locationNCT07240194
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+19 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Acute Myeloid LeukemiaTP53
Masonic Cancer Center, University of Minnesota32 enrolled1 locationNCT07008638
Recruiting
Phase 2

Oral-ATO for TP53-mutated Myeloid Malignancies

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Neoplasm+2 more
The University of Hong Kong30 enrolled1 locationNCT06778187
Recruiting
Phase 2

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell LymphomaTP53
The First Affiliated Hospital of Xiamen University52 enrolled1 locationNCT06158399
Recruiting
Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992
Recruiting
Phase 1

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Solid Tumor, AdultLymphomaEphA2 Overexpression+4 more
Chinese PLA General Hospital10 enrolled1 locationNCT05631886